Your browser doesn't support javascript.
loading
Potential Anti-Mpox Virus Activity of Atovaquone, Mefloquine, and Molnupiravir, and Their Potential Use as Treatments.
Akazawa, Daisuke; Ohashi, Hirofumi; Hishiki, Takayuki; Morita, Takeshi; Iwanami, Shoya; Kim, Kwang Su; Jeong, Yong Dam; Park, Eun-Sil; Kataoka, Michiyo; Shionoya, Kaho; Mifune, Junki; Tsuchimoto, Kana; Ojima, Shinjiro; Azam, Aa Haeruman; Nakajima, Shogo; Park, Hyeongki; Yoshikawa, Tomoki; Shimojima, Masayuki; Kiga, Kotaro; Iwami, Shingo; Maeda, Ken; Suzuki, Tadaki; Ebihara, Hideki; Takahashi, Yoshimasa; Watashi, Koichi.
Affiliation
  • Akazawa D; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan.
  • Ohashi H; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan.
  • Hishiki T; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan.
  • Morita T; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan.
  • Iwanami S; Interdisciplinary Biology Laboratory, Graduate School of Science, Nagoya University, Nagoya, Japan.
  • Kim KS; Interdisciplinary Biology Laboratory, Graduate School of Science, Nagoya University, Nagoya, Japan.
  • Jeong YD; Department of Science System Simulation, Pukyong National University, Busan, South Korea.
  • Park ES; Department of Mathematics, Pusan National University, Busan, South Korea.
  • Kataoka M; Interdisciplinary Biology Laboratory, Graduate School of Science, Nagoya University, Nagoya, Japan.
  • Shionoya K; Department of Mathematics, Pusan National University, Busan, South Korea.
  • Mifune J; Department of Veterinary Science, National Institute of Infectious Diseases, Tokyo, Japan.
  • Tsuchimoto K; Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.
  • Ojima S; Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan.
  • Azam AH; Department of Applied Biological Science, Tokyo University of Science, Noda, Japan.
  • Nakajima S; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan.
  • Park H; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan.
  • Yoshikawa T; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan.
  • Shimojima M; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan.
  • Kiga K; Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan.
  • Iwami S; Interdisciplinary Biology Laboratory, Graduate School of Science, Nagoya University, Nagoya, Japan.
  • Maeda K; Department of Virology I, National Institute of Infectious Diseases, Tokyo, Japan.
  • Suzuki T; Department of Virology I, National Institute of Infectious Diseases, Tokyo, Japan.
  • Ebihara H; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan.
  • Takahashi Y; Interdisciplinary Biology Laboratory, Graduate School of Science, Nagoya University, Nagoya, Japan.
  • Watashi K; Institute of Mathematics for Industry, Kyushu University, Fukuoka, Japan.
J Infect Dis ; 228(5): 591-603, 2023 08 31.
Article in En | MEDLINE | ID: mdl-36892247
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Mefloquine / Monkeypox virus Type of study: Prognostic_studies Limits: Humans Language: En Journal: J Infect Dis Year: 2023 Document type: Article Affiliation country: Japan
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Mefloquine / Monkeypox virus Type of study: Prognostic_studies Limits: Humans Language: En Journal: J Infect Dis Year: 2023 Document type: Article Affiliation country: Japan